You are here: Industry Insights > Tislelizumab

News List

Asieris Announces the World's First Patient Dose Administered in Combination of Asieris'APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients prnasia
January 04, 2022
Asieris Pharmaceuticals (Asieris), a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors, today announced that the world's first patient dose...
The U.S. FDA Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients prnasia
June 15, 2021
Asieris today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients with MIBC.
Tislelizumab reduces risk of death by 30 percent in oesophageal cancer trial europeanpharmaceuticalreview
June 08, 2021
In a Phase III trial, Novartis’ investigational checkpoint inhibitor tislelizumab improved overall survival in patients with oesophageal squamous cell carcinoma.
Novartis Tislelizumab Meets Primary Endpoint of Overall Survival in Esophageal Cancer americanpharmaceuticalreview
June 08, 2021
Novartis announced results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall survival (OS) versus chemotherapy (median 8.6 months vs. 6.3 months, p=0.0001).
Novartis Expands Oncology Pipeline with In-Licensing of Tislelizumab from BeiGene americanpharmaceuticalreview
January 20, 2021
Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene in major markets outside of China. Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages.
BeiGene announces collaboration with Novartis to develop and commercialize anti-PD-1 antibody Tislelizumab pharmaceutical-business-review
January 14, 2021
BeiGene announced a collaboration and license agreement with Novartis Pharma AG to develop, manufacture and commercialize BeiGene’s anti-PD-1 antibody tislelizumab in the United States, Canada, Mexico, member countries of the European Union ...
BeiGene submits application for the fifth indication for Tislelizumab Injection PharmaSources/Xiaoyaowan
June 30, 2020
On June 29, the official website of CDE showed that the PD-1 antibody of BeiGene submitted a new indication application for Tislelizumab injection and was accepted.
Chi-Med, BeiGene Enter Clinical Collaboration contractpharma
May 27, 2020
Will evaluate combinations of surufatinib and fruquintinib with tislelizumab for multiple solid tumor cancer indications.
First company awarded market authorisation under new Chinese drug law europeanpharmaceuticalreview
January 07, 2020
The mAb tislelizumab has been granted approval from Chinese authorities, making Boehringer Ingelheim Biopharmaceuticals the first MAH under the new system.
BeiGene’s Tislelizumab Achieves Positive Phase II Results contractpharma
July 19, 2019
Investigational anti-PD-1 antibody aims to treat Chinese patients with relapsed/refractory classical Hodgkin’s lymphoma.

Previous page 1 2 Next page